LONDON (Reuters) - GlaxoSmithKline plans 275 million pounds ($361 million) of new investments at three drug manufacturing sites in Britain, signaling its confidence in the country despite last month's vote to leave the European Union.
Reuters: Business News, Reuters: Business
Wed, 07/27/2016 - 12:23am